Who Exports Daratumumab from India — 36 Suppliers Behind a $1.3M Market
India's daratumumab export market is supplied by 36 active exporters who collectively shipped $1.3M across 209 shipments. VAMA LIFECARE PRIVATE LIMITED leads with a 20.1% market share, followed by NIVIRA EXPORTS and M. CARE. The top 5 suppliers together control 59.0% of total export value, reflecting a moderately competitive market structure.
Top Daratumumab Exporters from India — Ranked by Export Value
VAMA LIFECARE PRIVATE LIMITED is the leading daratumumab exporter from India, holding a 20.1% share of the $1.3M market across 209 shipments from 36 exporters. The top 5 suppliers — VAMA LIFECARE PRIVATE LIMITED, NIVIRA EXPORTS, M. CARE, DOSHI MEDICARE PRIVATE LIMITED, 3S PHARMACEUTICALS INDIA PRIVATE LIMITED — collectively control 59.0% of total export value, indicating a moderately concentrated market. Individual shares are: VAMA LIFECARE PRIVATE LIMITED (20.1%), NIVIRA EXPORTS (19.1%), M. CARE (7.6%), DOSHI MEDICARE PRIVATE LIMITED (7.4%), 3S PHARMACEUTICALS INDIA PRIVATE LIMITED (4.9%).
Top Daratumumab Exporters from India
Ranked by export value · 36 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | VAMA LIFECARE PRIVATE LIMITED DARATUMUMAB 400 MG BRAND NAME DARZALEX400 MG/20 ML | $268.2K | 1 | 20.1% |
| 2 | NIVIRA EXPORTS DARATUMUMAB 400 MG BRAND NAME DARZALEX400 MG/20 ML | $255.1K | 1 | 19.1% |
| 3 | M. CARE | $102.1K | 1 | 7.6% |
| 4 | DOSHI MEDICARE PRIVATE LIMITED | $98.7K | 1 | 7.4% |
| 5 | 3S PHARMACEUTICALS INDIA PRIVATE LIMITED DARATUMUMAB INJECTION 400 MG /20ML | $64.9K | 2 | 4.9% |
| 6 | VEA IMPEX (I) PRIVATE LIMITED DARZALEX 400MG INJ DARATUMUMABDARATUMUMAB CONCENTRATE 400 INJ | $57.9K | 2 | 4.3% |
| 7 | HUMANIQE BIOPHARMACEUTICALS PRIVATE LIMITED | $55.1K | 1 | 4.1% |
| 8 | RMPL PHARMA LLP DARZALEX 400MG VLSDARZALEX 400MG DARATUMUMAB | $55.0K | 1 | 4.1% |
| 9 | G P INTERGLOBE DARATUMUMAB 400 MG BRAND NAME DARZALEX400 MG/20 MLDARATUMUMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400 MGDARATUMUMAB CONCENTRATE FOR SOLUTION FORINFUSION 400 MG, | $54.0K | 1 | 4.0% |
| 10 | MILES INTERNATIONAL | $49.2K | 2 | 3.7% |
| 11 | MEDEX PHARMACEUTICALS DORZALEX 400MG 20MLDARZALEX 400MG 20MLDORZALEX 100MG 5ML | $35.3K | 1 | 2.6% |
| 12 | ALLEVIARE LIFE SCIENCES PRIVATE LIMITED DARATUMUMAB 400 MG BRAND NAME DARZALEX400 MG/20 ML | $31.0K | 2 | 2.3% |
| 13 | MELON GLOBALCARE DARATUMUMAB 400 MG BRAND NAME DARZALEX400 MG/20 ML | $27.4K | 1 | 2.0% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Daratumumab exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| VAMA LIFECARE PRIVATE LIMITED | Not Listed | Yes (as of March 202 | No | Not verified | WHO-GMP certification confirmed as of March 2026. |
| NIVIRA EXPORTS | Not Listed | Yes (as of March 202 | No | Not verified | WHO-GMP certification confirmed as of March 2026. |
| M. CARE | Not Listed | Yes (as of March 202 | No | Not verified | WHO-GMP certification confirmed as of March 2026. |
| DOSHI MEDICARE PRIVATE LIMITED | Not Listed | Yes (as of March 202 | No | Not verified | WHO-GMP certification confirmed as of March 2026. |
| 3S PHARMACEUTICALS INDIA PRIVATE LIMITED | Not Listed | Yes (as of March 202 | No | Not verified | WHO-GMP certification confirmed as of March 2026. |
| VEA IMPEX (I) PRIVATE LIMITED | Not Listed | Yes (as of March 202 | No | Not verified | WHO-GMP certification confirmed as of March 2026. |
| HUMANIQE BIOPHARMACEUTICALS PRIVATE LIMITED | Not Listed | Yes (as of March 202 | No | Not verified | WHO-GMP certification confirmed as of March 2026. |
| RMPL PHARMA LLP | Not Listed | Yes (as of March 202 | No | Not verified | WHO-GMP certification confirmed as of March 2026. |
| G P INTERGLOBE | Not Listed | Yes (as of March 202 | No | Not verified | WHO-GMP certification confirmed as of March 2026. |
| MILES INTERNATIONAL | Not Listed | Yes (as of March 202 | No | Not verified | WHO-GMP certification confirmed as of March 2026. |
TransData Nexus reviewed the regulatory standing of 10 leading Daratumumab exporters from India. 0 hold US FDA facility approvals, 10 maintain WHO-GMP certification, and 0 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Daratumumab sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its extensive production of active pharmaceutical ingredients (APIs). The city's pharmaceutical ecosystem is supported by a robust infrastructure, including research institutions and manufacturing facilities, making it a pivotal hub for API production. While Hyderabad's primary focus is on APIs, the presence of comprehensive supply chains and skilled labor also facilitates the production of complex biologics like Daratumumab.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a prominent center for pharmaceutical formulations. This region hosts numerous companies specializing in the development and manufacturing of finished dosage forms. The availability of advanced manufacturing technologies and a skilled workforce makes this cluster well-suited for producing injectable biologics such as Daratumumab. Additionally, the presence of equipment manufacturers, like those producing ampoule filling and sealing machines, supports the region's capability in sterile injectable production.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai, being a major commercial hub, provides logistical advantages for international trade. Several pharmaceutical companies and distributors in this region are involved in the export of Daratumumab, leveraging the well-established infrastructure and proximity to major ports. For instance, companies like R S Healthcare and 3S Corporation, based in Mumbai, are known for supplying Daratumumab injections.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh is recognized as a significant pharmaceutical manufacturing zone, largely due to favorable tax incentives. This region has attracted numerous pharmaceutical companies, contributing to its status as a major production hub. The cluster's focus is primarily on large-scale manufacturing, which may include the production of biologics like Daratumumab.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the technical expertise and manufacturing capabilities of suppliers, especially for complex biologics like Daratumumab.
- Leverage Export Hubs: Utilize the logistical advantages of export-oriented clusters like Mumbai-Thane-Raigad for efficient international distribution.
- Monitor Regulatory Compliance: Ensure that suppliers adhere to international quality standards and regulatory requirements to maintain product integrity.
By strategically sourcing from these specialized clusters, companies can optimize their supply chain for Daratumumab, ensuring consistent quality and supply reliability.
Common Questions — Daratumumab Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which daratumumab supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, VAMA LIFECARE PRIVATE LIMITED leads with 29 recorded shipments worth $268.2K. NIVIRA EXPORTS (33 shipments) and M. CARE (6 shipments) are also established high-volume exporters.
Q How many daratumumab manufacturers are there in India?
India has 36 active daratumumab exporters with a combined export market of $1.3M across 209 shipments to 23 countries. The top 5 suppliers hold 59.0% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for daratumumab from India?
Average FOB unit price: $1001.99 per unit, ranging from $0.81 to $6136.46. Average shipment value: $6.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 36 verified Indian exporters of Daratumumab ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 209 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 23 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
209 Verified Shipments
36 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists